Вопросы вирусологии. 2016; 61: 16-20
Разработка квадривалентной живой гриппозной вакцины, включающей реассортантные вирусы гриппа В антигенных линий Виктория и Ямагата
https://doi.org/10.18821/0507-4088-2016-61-1-16-20Аннотация
Список литературы
1. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28 (Suppl. 4): D45–53.
2. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization PracticesUnited States, 2013–2014. MMWR Recomm. Rep. 2013; 62 (RR-07): 1–43.
3. Toback S.L., Levin M.J., Block S.L., Belshe R.B., Ambrose C.S., Falloon J. Quadrivalent Ann Arbor strain live attenuated influenza vaccine. Expert Rev. Vaccines. 2012; 11(11): 1293–303.
4. Alexandrova G.I., Maassab H.F., Kendal A.P., Medvedeva T.E., Egorov A.Y., Klimov A.I. et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine. 1990; 8: 61–4.
5. Ларионова Н.В., Киселева И.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Малайзия/04/898 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2416639, 2009.
6. Ларионова Н.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Флорида/04/181 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2422519, 2010.
7. Ларионова Н.В., Руденко Л.Г., Александрова Г.И. Вакцинный штамм вируса гриппа В/60/Брисбен/08/83 для производства живой гриппозной интраназальной вакцины для взрослых и для детей. Патент РФ № 2422517, 2010.
8. World Health Organization Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
9. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 2012; 8(1): 81–8.
10. Романова Ю.Р., Александрова. Г.И. Интерференция и ее преодоление при репродукции двух штаммов вируса гриппа А в эксперименте. Вопросы вирусологии. 1993; 38(4): 149–52.
11. Руденко, Л.Г., Рамирес А., Барро М., Гущина М.И., Арманда Р.Е., Ермаченко Т.А. и др. Прививочные свойства живой гриппозной рекомбинантной вакцины типов А и В при раздельном и совместном применении детям 3-14 лет. Вопросы вирусологии. 1991; 36(6): 472-4.
12. Skowronski D.M., Hamelin M.E., Janjua N.Z., De Serres G., Gardy J.L., Rhéaume C. et al. Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. PLoS One. 2012; 7(6): e38929.
13. Xu X., Lindstrom S.E., Shaw M.W., Smith C.B., Hall H.E., Mungall B.A. et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004; 103(1–2): 55–60.
14. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi. T. et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 2012; 31(7): 745–51.
Problems of Virology. 2016; 61: 16-20
Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata
https://doi.org/10.18821/0507-4088-2016-61-1-16-20Abstract
References
1. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28 (Suppl. 4): D45–53.
2. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization PracticesUnited States, 2013–2014. MMWR Recomm. Rep. 2013; 62 (RR-07): 1–43.
3. Toback S.L., Levin M.J., Block S.L., Belshe R.B., Ambrose C.S., Falloon J. Quadrivalent Ann Arbor strain live attenuated influenza vaccine. Expert Rev. Vaccines. 2012; 11(11): 1293–303.
4. Alexandrova G.I., Maassab H.F., Kendal A.P., Medvedeva T.E., Egorov A.Y., Klimov A.I. et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine. 1990; 8: 61–4.
5. Larionova N.V., Kiseleva I.V., Rudenko L.G., Aleksandrova G.I. Vaktsinnyi shtamm virusa grippa V/60/Malaiziya/04/898 dlya proizvodstva zhivoi grippoznoi intranazal'noi vaktsiny dlya vzroslykh i dlya detei. Patent RF № 2416639, 2009.
6. Larionova N.V., Rudenko L.G., Aleksandrova G.I. Vaktsinnyi shtamm virusa grippa V/60/Florida/04/181 dlya proizvodstva zhivoi grippoznoi intranazal'noi vaktsiny dlya vzroslykh i dlya detei. Patent RF № 2422519, 2010.
7. Larionova N.V., Rudenko L.G., Aleksandrova G.I. Vaktsinnyi shtamm virusa grippa V/60/Brisben/08/83 dlya proizvodstva zhivoi grippoznoi intranazal'noi vaktsiny dlya vzroslykh i dlya detei. Patent RF № 2422517, 2010.
8. World Health Organization Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
9. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 2012; 8(1): 81–8.
10. Romanova Yu.R., Aleksandrova. G.I. Interferentsiya i ee preodolenie pri reproduktsii dvukh shtammov virusa grippa A v eksperimente. Voprosy virusologii. 1993; 38(4): 149–52.
11. Rudenko, L.G., Ramires A., Barro M., Gushchina M.I., Armanda R.E., Ermachenko T.A. i dr. Privivochnye svoistva zhivoi grippoznoi rekombinantnoi vaktsiny tipov A i V pri razdel'nom i sovmestnom primenenii detyam 3-14 let. Voprosy virusologii. 1991; 36(6): 472-4.
12. Skowronski D.M., Hamelin M.E., Janjua N.Z., De Serres G., Gardy J.L., Rhéaume C. et al. Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. PLoS One. 2012; 7(6): e38929.
13. Xu X., Lindstrom S.E., Shaw M.W., Smith C.B., Hall H.E., Mungall B.A. et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004; 103(1–2): 55–60.
14. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi. T. et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 2012; 31(7): 745–51.
